Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Arm, Multiple-Dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BMS-646256 in Obese and High Risk Overweight Subjects.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2010
Price :
$35
*
At a glance
- Drugs Ibipinabant (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 20 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 20 Mar 2008 Status changed from in progress to completed, in accordance with clinicaltrials.gov.
- 15 Jun 2007 Status changed from recruiting